• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lineage Cell Therapeutics Inc (NY: LCTX )

    0.8221 -0.0079 (-0.95%)
    Streaming Delayed Price Updated: 2:35 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lineage Cell Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
    Via Benzinga
    Lineage Cell Therapeutics's Return On Capital Employed Overview
    Via Benzinga
    Preview: Lineage Cell Therapeutics's Earnings
    Via Benzinga
    Lineage to Present at 2023 AAPS National Biotechnology Conference
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    3 Penny Stocks to Buy During Market Downturns
    If you're looking for penny stocks to buy that can weather economic turmoil, these should make the cut due to their strong fundamentals. 
    Via InvestorPlace
    Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology
    Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive option and license agreement with Eterna Therapeutics Inc for beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell... 
    Via Benzinga
    Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
    BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
    Via Benzinga
    CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
    Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
    Via Investor's Business Daily
    Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Earnings Preview: Lineage Cell Therapeutics
    Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that... 
    Via Benzinga
    Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
    Upgrades 
    Via Benzinga
    Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
    Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
    Via TheNewswire.com
    A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
    By David Willey, Benzinga 
    Via News Direct
    121 Stocks That Hit Their 52-Week Low
    New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
    Via Benzinga
    A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
    Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
    Via Benzinga
    Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.